[{"address1": "11711 N. Meridian Street", "address2": "Suite 300", "city": "Carmel", "state": "IN", "zip": "46032", "country": "United States", "phone": "(317) 659-0200", "website": "https://mbxbio.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial designed as a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies designed as a long-acting and highly potent GLP-1 and glucose-dependent insulinotropic polypeptide receptor co-agonist prodrug for treating obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.", "fullTimeEmployees": 36, "companyOfficers": [{"maxAge": 1, "name": "Mr. Peter Kent Hawryluk", "age": 54, "title": "CEO, President & Director", "yearBorn": 1969, "fiscalYear": 2023, "totalPay": 571200, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Steven J. Prestrelski M.B.A., MBA, Ph.D.", "age": 59, "title": "Chief Scientific Officer", "yearBorn": 1964, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Matt  Gambino", "title": "Vice President of Marketing", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Michelle  Graham", "age": 56, "title": "Chief Human Resources Officer", "yearBorn": 1967, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Salomon  Azoulay", "age": 66, "title": "Chief Medical Officer", "yearBorn": 1957, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 21.65, "open": 21.65, "dayLow": 20.935, "dayHigh": 22.72, "regularMarketPreviousClose": 21.65, "regularMarketOpen": 21.65, "regularMarketDayLow": 20.935, "regularMarketDayHigh": 22.72, "volume": 101382, "regularMarketVolume": 101382, "averageVolume": 1037000, "averageVolume10days": 1037000, "averageDailyVolume10Day": 1037000, "bid": 16.57, "ask": 21.9, "bidSize": 400, "askSize": 100, "marketCap": 684854528, "fiftyTwoWeekLow": 20.515, "fiftyTwoWeekHigh": 26.08, "fiftyDayAverage": 22.65, "twoHundredDayAverage": 22.65, "currency": "USD", "enterpriseValue": 440167808, "floatShares": 14361705, "sharesOutstanding": 31853700, "bookValue": -6.182, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -47200000, "trailingEps": -1.48, "enterpriseToEbitda": -8.679, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "MBX", "underlyingSymbol": "MBX", "shortName": "MBX Biosciences, Inc.", "longName": "MBX Biosciences, Inc.", "firstTradeDateEpochUtc": 1726234200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "a066c197-b79d-33dd-be3a-0bcc20467a16", "gmtOffSetMilliseconds": -14400000, "currentPrice": 21.5, "recommendationKey": "none", "totalCash": 55262000, "totalCashPerShare": 3.49, "ebitda": -50717000, "totalDebt": 249000, "quickRatio": 6.761, "currentRatio": 7.173, "debtToEquity": 0.457, "operatingCashflow": -42852000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-09-17"}]